On April 13, 2018, the United States intervened in five lawsuits accusing Insys Therapeutics Inc., of violating the False Claims Act in connection with the marketing of Subsys, an opioid painkiller manufactured and sold by Insys, the Department of Justice announced today.  Subsys is a sublingual spray form of fentanyl, a powerful, but highly addictive, opioid painkiller.  In 2012, Subsys was approved by the Food and Drug Administration for the treatment of persistent breakthrough pain in adult cancer patients who are already receiving, and tolerant to, around-the-clock opioid therapy.

An injection may one day be able to reverse atherosclerosis, according to emerging research presented at the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, a premier global exchange of the latest advances in vascular biology for researchers and clinicians.

Halena Gazelka, M.D., chair, Mayo Clinic Opioid Stewardship Program, has been appointed by U.S. Department of Health and Human Services Secretary Alex Azar to serve on the newly established Pain Management Best Practices Inter-Agency Task Force. Established by the Comprehensive Addiction and Recovery Act of 2016, the task force will identify inconsistencies in pain management best practices among federal agencies and propose solutions to resolve these inconsistencies.

Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and Children’s Hospital Colorado are collaborating to provide solutions for patients with hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of the heart is severely underdeveloped.

Mayo Clinic continues its move to a single, integrated electronic health record and billing system with the implementation of Epic at its Rochester campus.

Mark A. Atkinson, PhD, has been selected to receive the American Diabetes Association’s® (ADA’s) 2018 Albert Renold Award. This award recognizes an individual whose career is distinguished by outstanding achievements in the training and mentorship of diabetes research scientists and in the facilitation of diabetes research. Dr. Atkinson will be recognized with this honor during the ADA’s 78th Scientific Sessions, June 22-26, 2018, at the Orange County Convention Center in Orlando.